Related Experiment Videos
Cervical cancer staging
Sergio Pecorelli1, Franco Odicino
1Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, University of Brescia, Brescia, Italy. pecorelli@iol.it
Cancer Journal (Sudbury, Mass.)
|December 24, 2003
Summary
The FIGO staging system for cervical cancer, established in 1950, relies on clinical examination for staging. Adhering to these rules is crucial for comparing treatment outcomes in cervical cancer care.
Area of Science:
- Gynecologic Oncology
- Clinical Staging Systems
Background:
- The International Classification of the Stages of Carcinoma of the Uterine Cervix was established in 1950, with revisions primarily affecting Stage I.
- The FIGO staging system for cervical cancer is based on clinical examination at the time of diagnosis to determine anatomical extent of disease.
Purpose of the Study:
- To emphasize the importance of strict adherence to clinical staging rules for accurate comparison of cervical cancer treatment outcomes.
- To discuss the feasibility and limitations of surgical-pathologic staging in cervical cancer, particularly in resource-limited settings.
Main Methods:
- Review of the historical development and current application of the FIGO staging system for cervical cancer.
- Analysis of the clinical versus surgical-pathologic staging approaches for cervical cancer.
Main Results:
- Cervical cancer staging remains primarily clinical under the FIGO system.
- Surgical-pathologic staging is often impractical for advanced disease or radiation-treated patients, especially in regions with limited healthcare resources.
Conclusions:
- Consistent application of the FIGO clinical staging system is essential for reliable comparison of treatment results in cervical cancer.
- While clinical staging is standard, surgical and pathological data remain valuable for detailed survival and prognostic factor analysis in cervical cancer research.